| scholarly article | Q13442814 |
| P356 | DOI | 10.3389/FPHAR.2018.01271 |
| P8608 | Fatcat ID | release_7jiqfjekynaivmplueshmgbiz4 |
| P932 | PMC publication ID | 6224489 |
| P698 | PubMed publication ID | 30450051 |
| P50 | author | Iwona Ciechomska | Q58631767 |
| P2093 | author name string | Bozena Kaminska | |
| Judyta Jackl | |||
| Marta Patrycja Marciniak | |||
| P2860 | cites work | LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation | Q24294635 |
| G9a and Glp methylate lysine 373 in the tumor suppressor p53 | Q24298004 | ||
| Functional Role of G9a Histone Methyltransferase in Cancer | Q26781247 | ||
| Crosstalk between apoptosis, necrosis and autophagy | Q26829723 | ||
| Glioma stem cells promote radioresistance by preferential activation of the DNA damage response | Q27860541 | ||
| Stem cells, cancer, and cancer stem cells | Q27860878 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Chromatin modifications and their function | Q27861067 | ||
| Epigenetic regulation of autophagy by the methyltransferase G9a | Q28115438 | ||
| Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3 | Q28214048 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Autophagy: from phenomenology to molecular understanding in less than a decade | Q29614174 | ||
| A restricted cell population propagates glioblastoma growth after chemotherapy | Q29615605 | ||
| Cancer statistics, 2005 | Q29617572 | ||
| Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase | Q33272939 | ||
| Accumulation of low-dose BIX01294 promotes metastatic potential of U251 glioblastoma cells | Q33597842 | ||
| Autophagy genes as tumor suppressors | Q33787645 | ||
| Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma. | Q33936618 | ||
| Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. | Q35691532 | ||
| A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma | Q35701142 | ||
| Lysine methyltransferase G9a methylates the transcription factor MyoD and regulates skeletal muscle differentiation | Q35735009 | ||
| Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in in vitro and in vivo studies. | Q53677022 | ||
| Chromosomal instability, reproductive cell death and apoptosis induced by O6-methylguanine in Mex-, Mex+ and methylation-tolerant mismatch repair compromised cells: facts and models | Q74063639 | ||
| Temozolomide resistance in glioblastoma multiforme | Q91792247 | ||
| G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer | Q35858016 | ||
| Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells | Q36026945 | ||
| Postradiation sensitization of the histone deacetylase inhibitor valproic acid | Q36085669 | ||
| BIX-01294 treatment blocks cell proliferation, migration and contractility in ovine foetal pulmonary arterial smooth muscle cells | Q36831427 | ||
| Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity | Q37256069 | ||
| The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation | Q37425389 | ||
| BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells. | Q37487279 | ||
| The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma. | Q37725428 | ||
| H3K9 methyltransferase G9a and the related molecule GLP. | Q37865974 | ||
| Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results | Q38016227 | ||
| The effects of selected inhibitors of histone modifying enzyme on C6 glioma cells. | Q38987638 | ||
| Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells | Q38994487 | ||
| Endoplasmic reticulum stress triggers autophagy in malignant glioma cells undergoing cyclosporine a-induced cell death | Q39349204 | ||
| Valproic acid sensitizes human glioma cells for temozolomide and γ-radiation. | Q39450904 | ||
| H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. | Q39645130 | ||
| Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines | Q40126767 | ||
| Cyclosporine a induces growth arrest or programmed cell death of human glioma cells. | Q40387310 | ||
| The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. | Q40438982 | ||
| Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells | Q40600919 | ||
| Vorinostat(SAHA) Promotes Hyper-Radiosensitivity in Wild Type p53 Human Glioblastoma Cells. | Q42974434 | ||
| Endothelial differentiation of adipose-derived mesenchymal stem cells is improved by epigenetic modifying drug BIX-01294. | Q44814931 | ||
| Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid | Q45172727 | ||
| Pharmacological and transcriptional inhibition of the G9a histone methyltransferase suppresses proliferation and modulates redox homeostasis in human microvascular endothelial cells | Q46266480 | ||
| Involvement of the mismatch repair system in temozolomide-induced apoptosis | Q47752780 | ||
| Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines | Q48154511 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | temozolomide | Q425088 |
| P304 | page(s) | 1271 | |
| P577 | publication date | 2018-11-02 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide | |
| P478 | volume | 9 |
Search more.